PHP23 THE DRUG PRICE REFERENCE INDEX STUDY OF THE PHILIPPINE HEALTH INSURANCE CORPORATIONdoi:10.1016/S1098-3015(10)61831-1MR Valera and GM Roan and AB Dequito and B Palafox and EP Banzon and JQ WongValue in Health
Drugs & Medications Pill Identifier Interaction Checker Symptom Checker Side Effects Conditions & Diseases Treatment Guides Compare Drugs My Med List Discount Card FDA Alerts Price Guide Phonetic Search Health Professionals Previous Next ...
First, if there are already competing products in the NRDL, the price of these products will generally serve as the main reference. If the price gap is too large, the newcomers’ products typically will not be taken into consideration. Second, if there are no competing products...
A previous study has suggested that drug price adjustments allow physicians in Taiwan to gain greater profit by prescribing generic drugs. To better understand the effect of price adjustments on physician choice, this study used renin-angiotensin drugs (including angiotensin-converting enzyme inhibitors ...
Rational use of drugs in populations. For the individual patient, the rational use of a drug implies the prescription of a well-documented drug at an optimal dose, together with the correct information, at an affordable price. Without knowledge of how drugs are being prescribed and used, it ...
A price increase is unavoidable due to the increased demand out of the supply chain restrictions such as in pandemic conditions. The cost of the API is the most significant component of the pharmaceutical cost of production. Policymakers at the world’s largest pharmaceutical market (the US) and...
In the absence of any PBM rebates, an inflation penalty would not be expected to be associated with a price reduction, as the manufacturer may simply pay the rebate and achieve the same net price while gaining the value of a higher reference price for future products. However, PBMs generally...
FDB is the world’s trusted drug database leader. Enabling medication decision support we partner with customers to help improve safety, efficiency and outcomes.
It is based on the reference: Drug Doses, by Frank Shann, 17th edition, Melbourne, Australia, 2017, Collective Pty, Limited, ISBN: 9780648005308. While every effort has been made to ensure the accuracy of the content, the authors and developers cannot guarantee that it is free from errors ...
[18] Other treatments that have recently entered the market have not matched the efficacy of sofosbuvir, however, allowing Gilead to set a higher price until additional competition enters the market.[18] Patient advocates such as Doctors Without Borders have complained about the price, which is ...